The High Health Authority Has Refused Access to Vasopressin for Septic Shock: Patients Are not Being Given the Best Possible Chance!
DOI:
https://doi.org/10.3166/rea-2019-0112Keywords:
Diaphragm, Ultrasound, WeaningAbstract
Septic shock still places a burden to the healthcare systems worldwide owing to its high incidence and morbimortality. Recent international guidelines have suggested vasopressin as a second-line vasopressor therapy in norepinephrine-treated patients. Vasopressin is now broadly used in many countries in the routine management of septic shock. Vasopressin has received marketing authorization by the European medicine agency on May 31, 2018. Yet, recently, the French High Health Authority refused vasopressin registration in France. The current manuscript aimed at investigating the discrepancies in the interpretations of evidence-based data between the French High Health Authority and scientific societies that have endorsed the Surviving Sepsis Campaign guidelines.